Development

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles

A recently released industry guide outlines a science- and risk-based approach to control the risk of cross-contamination.

Risk Mitigation in High-Potency Manufacturing

Sean Milmo is a freelance writer based in Essex, UK.

Public-private R&D partnerships are on the rise across Europe, but national goals and academia-industry competition could prevent their success at the European level.

Report from Europe

The author describes the development of small-angle X-ray scattering and analyzes its advantages in the characterization of drug-delivery systems and large molecules. This article is part of a special Analytical Technology issue.

Small-Angle X-ray Scattering for Pharmaceutical Applications

Reinhard Vollmer is Head of Technical Competence Center of JRS Pharma (Germany).

Edmont Stoyanov is Senior Scientist at JRS Pharma (Germany).

Using new co-processing technologies, the authors show that it is possible to formulate an 'all-round' excipient.

An All-Round Excipient For Direct Compression

The European Medicines Agency and the US Food and Drug Administration announced their individual regulatory decisions and resulting actions regarding the marketing of GlaxoSmithKline's (London) Avandia (rosiglitazone), a thiazolidinedione used to treat Type 2 diabetes.

EMA and FDA Take Action on GSK's Avandia

Novartis Sells US Enablex Rights; Ricerca Names Chemistry Director; And More.

Week of Sept. 27, 2010: Company and People Notes: Novartis Sells US Enablex Rights; Ricerca Names Chemistry Director; And More.

DSM and PolyTherics in Development Deal; Kite Pharma Appoints President and CEO, And More.

Week of Sept. 20, 2010: Company and People Notes: DSM and PolyTherics in Development Deal; Kite Pharma Appoints President and CEO, And More.

Johnson & Johnson (J&J, New Brunswick, NJ) announced last week that it was in "advanced negotiations" for a potential public offer for the Dutch biopharmaceutical company Crucell (Leiden, The Netherlands).

Johnson & Johnson in Negotiations to Buy Crucell

Genzyme Sells Genetics Business; Bausch and Lomb Names Vice-President; and More.

Week of Sept. 13, 2010: Company and People Notes: Genzyme Sells Genetics Business; Bausch and Lomb Names Vice-President; and More.

Bristol-Myers Squibb (New York) has agreed to acquire the biopharmaceutical company ZymoGenetics (Seattle) for an aggregate purchase price of $885 million or $735 million net of cash.

Ingredients